In the glucose tolerance model, LASSBio-2129 (10 mg/kg, i.p.)reduced blood glucose and AUC, increased muscle and liver glycogen content, and increased GLUT4 expression in skeletal muscle; additionally, it attenuated dexamethasone-induced insulin resistance, with a magnitude comparable to that of sitagliptin at the same dose. The gene discussed is SLC2A4; the disease is Insulin resistance.